Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 11, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "COCP". The report primarily serves to disclose a scheduled investor presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material financial changes or operational updates are reported in this filing. The document solely announces the Company's participation in an external conference.
Guidance, Outlook, and Management Commentary
Beginning on January 11, 2021, senior executives participated in the BioConnect 2021 Conference hosted by H.C. Wainwright & Co., LLC. An investor presentation was furnished as Exhibit 99.1 and is available on the Company's website. The filing explicitly states that the information in this Item 7.01 and the associated presentation shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the content of the investor presentation (Exhibit 99.1) on the Company's website for specific business updates.
- Note that the presentation materials are not legally "filed" with the SEC and do not carry the same liability protections as formal filings.
- Confirm the Company's status as an emerging growth company (unchecked in this filing) and its listing on the Nasdaq Capital Market.